RPS: Brexit poses counterfeit medicines risk as FMD benefits lost
The government must put “robust plans” in place to ensure counterfeit medicines don’t enter the supply chain as FMD ceases to apply across the UK post Brexit, the RPS has said.
The Royal Pharmaceutical Society (RPS) is “concerned” that removal of EU anti-counterfeit drugs legislation known as the Falsified Medicines Directive (FMD)could leave the UK
Do you think FMD should be kept after the transition period ends?